Home › Funds › Boxer Capital Management, LLC › PCVX
Boxer Capital Management, LLC position in PCVX
VAXCYTE INC · Health Care
Boxer Capital Management, LLC reported holding 325,000 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$18.9M, representing 1.42% of its reported portfolio and ranking #17 among its reported holdings. Boxer Capital Management, LLC has disclosed PCVX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Boxer Capital Management, LLC's PCVX position evolved
Boxer Capital Management, LLC first disclosed a stake in PCVX in Q1 2026 at 325,000 shares (US$18.9M). The position peaked in Q2 2026 at 325,000 shares, worth US$18.9M. Across 2 filings, Boxer Capital Management, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 325,000 shares valued at US$18.9M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 325.00K | $18.89M | New |
| Q2 2026 | 325.00K | $18.89M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PCVX and 13F data
PCVX (VAXCYTE INC) is a Health Care company. 36 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PCVX
- Jupiter Topco LLC 17.97M sh · $1.04B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M sh · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M sh · $667.02M · Q2 2026
- Deep Track Capital, LP 4.30M sh · $249.96M · Q2 2026
- Kynam Capital Management, LP 2.92M sh · $169.88M · Q2 2026
- Caligan Partners LP 2.19M sh · $127.23M · Q2 2026
- Paradigm Biocapital Advisors LP 2.13M sh · $123.69M · Q2 2026
- Bellevue Group AG 1.97M sh · $114.63M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- MAVERICK CAPITAL LTD 1.61M sh · $93.78M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.43M sh · $82.86M · Q2 2026
More on Boxer Capital Management, LLC
FAQ
How long has Boxer Capital Management, LLC held PCVX?
Boxer Capital Management, LLC has disclosed PCVX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Boxer Capital Management, LLC's current position in PCVX?
As of Q2 2026, Boxer Capital Management, LLC holds 325.00K shares of PCVX (VAXCYTE INC), valued at $18.89M, representing 1.42% of its reported portfolio and ranking #17.
Has Boxer Capital Management, LLC been buying or selling PCVX?
In the latest 13F filing (Q2 2026), Boxer Capital Management, LLC held unchanged its position in PCVX. The position peaked in Q2 2026 at 325.00K shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.